The receipt of the State Food and Drug Administration (SFDA) certificates will allow Chindex to begin the sales process and launch official marketing programs for these products, creating a wealth of new market opportunities for the company.
Roberta Lipson, CEO of Chindex, said: “We have been in preparatory discussions for many months with potential hospital customers in China related to the exciting daVinci S product. We will now begin immediately to move ahead with the sales process for the prospects in our pipeline.”